Mostrar el registro sencillo del ítem

dc.contributor.authorCavero-Redondo I.
dc.contributor.authorSoriano-Cano A.
dc.contributor.authorÁlvarez-Bueno C.
dc.contributor.authorCunha P.G.
dc.contributor.authorMartínez-Hortelano J.A.
dc.contributor.authorGarrido-Miguel M.
dc.contributor.authorBerlanga-Macías C.
dc.contributor.authorMartínez-Vizcaíno V.
dc.date.accessioned2020-09-02T22:14:46Z
dc.date.available2020-09-02T22:14:46Z
dc.date.issued2018
dc.identifier10.1161/JAHA.118.009833
dc.identifier.citation7, 18, -
dc.identifier.issn20479980
dc.identifier.urihttps://hdl.handle.net/20.500.12728/3973
dc.descriptionpredictors of atherosclerotic-related disorders. This study aimed to estimate the relationship between advanced glycation end products indicated by skin autofluorescence levels and the risk of cardiovascular and all-cause mortality based on data from observational studies. Methods and Results-—We systematically searched Medline, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and the Web of Science databases from their inceptions until November 2017 for observational studies addressing the association of advanced glycation end products by skin autofluorescence levels with cardiovascular and all-cause mortality. The DerSimonian and Laird random-effects method was used to compute pooled estimates of hazard ratios and their respective 95% confidence intervals for the risk of cardiovascular and all-cause mortality associated with levels of advanced glycation end products by skin autofluorescence. Ten published studies were included in the systematic review and meta-analysis. Higher skin autofluorescence levels were significantly associated with a higher pooled risk estimate for cardiovascular mortality (hazard ratio: 2.06; 95% confidence interval, 1.58–2.67), which might not be important to moderate heterogeneity (I2=34.7%; P=0.163), and for all-cause mortality (hazard ratio: 1.91; 95% confidence interval, 1.42–2.56) with substantial heterogeneity (I2=60.8%; P=0.0.18). Conclusions-—Our data suggest that skin autofluorescence levels could be considered predictors of all-cause mortality and cardiovascular mortality in patients at high and very high risk. © 2018 The Authors.
dc.language.isoen
dc.publisherAmerican Heart Association Inc.
dc.subjectAdvanced glycation end products
dc.subjectCardiovascular complications
dc.subjectMeta-analysis
dc.subjectMortality
dc.subjectSkin autofluorescence
dc.subjectadvanced glycation end product
dc.subjectadvanced glycation end product
dc.subjectbiological marker
dc.subjectall cause mortality
dc.subjectautofluorescence
dc.subjectcardiovascular mortality
dc.subjecthigh risk population
dc.subjecthuman
dc.subjectmortality risk
dc.subjectprediction
dc.subjectpriority journal
dc.subjectReview
dc.subjectrisk assessment
dc.subjectskin
dc.subjectskin autofluorescence
dc.subjectsystematic review
dc.subjectcardiovascular disease
dc.subjectcause of death
dc.subjectdiagnostic imaging
dc.subjectglobal health
dc.subjectincidence
dc.subjectluminescence
dc.subjectmeta analysis
dc.subjectmetabolism
dc.subjectpredictive value
dc.subjectprocedures
dc.subjectrisk factor
dc.subjectskin
dc.subjectsurvival rate
dc.subjectBiomarkers
dc.subjectCardiovascular Diseases
dc.subjectCause of Death
dc.subjectGlobal Health
dc.subjectGlycation End Products, Advanced
dc.subjectHumans
dc.subjectIncidence
dc.subjectLuminescent Measurements
dc.subjectPredictive Value of Tests
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.subjectSkin
dc.subjectSurvival Rate
dc.titleSkin autofluorescence–indicated advanced glycation end products as predictors of cardiovascular and all-cause mortality in high-risk subjects: A systematic review and meta-analysis
dc.typeReview


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem